There has always been some tension between proponents of hypothesis-driven and discovery-driven research in the broad field of life sciences. Academic research has been primarily focused on hypothesis-driven research. However, the success of the human genome project, a discovery-driven research approach, has opened the door to adding other types of discovery-driven research to a continuum of research approaches. In contrast, drug discovery research in the pharmaceutical industry has embraced discovery-driven research for many years. A good example has been the discovery of active compounds from large chemical libraries, through screening campaigns. The success of the human genome project has also demonstrated the need for both academic researchers and industrial researchers to now understand the functions of genes and gene products. The cell is the basic unit of life and it has been at the cellular level where function can be demonstrated most cost-effectively and rapidly. High content screening (HCS) was developed by Cellomics Inc. in the mid-1990s to address the need for a platform that could be used in the discovery-driven research and development required to understand the functions of genes and gene products at the level of the cell.
"synopsis" may belong to another edition of this title.
High content screening (HCS) was developed by Cellomics Inc. in the mid-1990s to address the need for a platform that could be used in the discovery-driven research and development required to understand the functions of genes and gene products at the level of the cell. High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery discusses its use as a high throughput platform to understand the functions of genes, RNA, proteins, and other cellular constituents at the level of the living cell.
High Content Screening is assembled to assist both existing users of HCS, as well as investigators considering the addition of a discovery-driven platform to their research and development activities. The chapters have been organized into sections that highlight the importance of integrating instrumentation, application software, reagents, and informatics. In addition, there is a combination of pure review chapters on key topics and specific methods chapters.
"About this title" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # MUALW3SQYY
Quantity: Over 20 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 14384721-n
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In. Seller Inventory # ria9781617377464_new
Quantity: Over 20 available
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New. Seller Inventory # 14384721-n
Quantity: Over 20 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -There has always been some tension between proponents of hypothesis-driven and discovery-driven research in the broad field of life sciences. Academic research has been primarily focused on hypothesis-driven research. However, the success of the human genome project, a discovery-driven research approach, has opened the door to adding other types of discovery-driven research to a continuum of research approaches. In contrast, drug discovery research in the pharmaceutical industry has embraced discovery-driven research for many years. A good example has been the discovery of active compounds from large chemical libraries, through screening campaigns. The success of the human genome project has also demonstrated the need for both academic researchers and industrial researchers to now understand the functions of genes and gene products. The cell is the basic unit of life and it has been at the cellular level where function can be demonstrated most cost-effectively and rapidly. High content screening (HCS) was developed by Cellomics Inc. in the mid-1990s to address the need for a platform that could be used in the discovery-driven research and development required to understand the functions of genes and gene products at the level of the cell. 464 pp. Englisch. Seller Inventory # 9781617377464
Quantity: 2 available
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Paperback / softback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days. Seller Inventory # C9781617377464
Quantity: Over 20 available
Seller: moluna, Greven, Germany
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Part I. Introduction to High Content Screening Past, Present, and Future of High Content Screening and the Field of Cellomics D. Lansing Taylor A Pharmaceutical Company User s Perspective on the Potential of High Content Screening in Drug Discovery Ann F. Seller Inventory # 458521603
Quantity: Over 20 available
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 462. Seller Inventory # 262571979
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand pp. 462 66:B&W 7 x 10 in or 254 x 178 mm Perfect Bound on White w/Gloss Lam. Seller Inventory # 5275924
Quantity: 4 available
Seller: preigu, Osnabrück, Germany
Taschenbuch. Condition: Neu. High Content Screening | D Lansing Taylor | Taschenbuch | 464 S. | Englisch | 2010 | Humana Press | EAN 9781617377464 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Seller Inventory # 107146359
Quantity: 5 available